| Name | Title | Contact Details |
|---|
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
Interlace Medical, Inc. is a Framingham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
American Habilitation Svc is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kidsvision is a Jackson, MS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bronx AIDS Services (BAS), an AIDS service organization, helps more than 25,000 Bronx residents each year with an array of free services designed to meet the needs of this ethnically and culturally diverse community. Our services include: Extensive